Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in High-risk BCMA+ Multiple Myeloma
NCT04617704Phase 1Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Incidence and severity of adverse events after GC012F injection at 2 years. Status: unknown.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04617704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617704.